China’s MOH Issues Notice On Strengthening Drug Use Surveillance
This article was originally published in PharmAsia News
Executive SummaryChina's Ministry of Health recently circulated a working draft on strengthening rational drug use surveillance nationwide. The scheme is jointly formulated by MOH, State Administration of Traditional Chinese Medicine and the health bureau under the General Logistics Department of the People's Liberation Army. MOH demands that all provincial-level health authorities instruct monitoring site hospitals in each council area to implement relevant work; these hospitals should ensure smooth progress in their surveillance. MOH will mainly be responsible for the surveillance work in grade three hospitals, while provincial health authorities will be in charge of rational drug use monitoring in grade two hospitals and basic-level health care institutions. (Click here for more - Chinese Language)
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.